Bayer ’s stivarga receives EU marketing approval for HCC treatment

The European Commission (EC) has granted marketing authorisation for Bayer ’s stivarga (regorafenib) used for the treatment of adult patients with hepatocellular carcinoma (HCC) who have been previously treated with nexavar (sorafenib).
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news